Bausch Health (Bausch Health) Gross Profit : $6,198 Mil (TTM As of Dec. 2023)

View and export this data going back to 1994. Start your Free Trial

What is Bausch Health Gross Profit?

Bausch Health's gross profit for the three months ended in Dec. 2023 was $1,703 Mil. Bausch Health's gross profit for the trailing twelve months (TTM) ended in Dec. 2023 was $6,198 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Bausch Health's gross profit for the three months ended in Dec. 2023 was $1,703 Mil. Bausch Health's Revenue for the three months ended in Dec. 2023 was $2,408 Mil. Therefore, Bausch Health's Gross Margin % for the quarter that ended in Dec. 2023 was 70.72%.

Bausch Health had a gross margin of 70.72% for the quarter that ended in Dec. 2023 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of Bausch Health was 75.26%. The lowest was 70.78%. And the median was 71.97%.

Bausch Health Gross Profit Historical Data

The historical data trend for Bausch Health's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bausch Health Gross Profit Chart

Bausch Health Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross Profit

Get a 7-Day Free Trial

6,251.00

5,778.00

6,040.00

5,760.00

6,198.00

Bausch Health Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Gross Profit	Get a 7-Day Free Trial															1,541.00	1,362.00	1,518.00	1,615.00	1,703.00

Competitive Comparison of Bausch Health's Gross Profit

For the Drug Manufacturers - Specialty & Generic subindustry, Bausch Health's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bausch Health's Gross Profit Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bausch Health's Gross Profit distribution charts can be found below:

* The bar in red indicates where Bausch Health's Gross Profit falls into.

Bausch Health Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Bausch Health's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )	=	Revenue	-	Cost of Goods Sold
	=	8757	-	2559
	=	6,198

Bausch Health's Gross Profit for the quarter that ended in Dec. 2023 is calculated as

Gross Profit (Q: Dec. 2023 )	=	Revenue	-	Cost of Goods Sold
	=	2408	-	705
	=	1,703

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $6,198 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Bausch Health's Gross Margin % for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )	=	Gross Profit (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	1,703	/	2408
	=	70.72 %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Bausch Health (NYSE:BHC) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Bausch Health had a gross margin of 70.72% for the quarter that ended in Dec. 2023 => Durable competitive advantage

Bausch Health Gross Profit Related Terms

Thank you for viewing the detailed overview of Bausch Health's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.

Bausch Health (Bausch Health) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bausch Health Companies Inc (NYSE:BHC) » Definitions » Gross Profit

Comparable Companies

Traded in Other Exchanges

BVF:Germany BVF:Germany BHC:Canada

Address

2150 Saint Elzear Boulvard West, Laval, QC, CAN, H7L 4A8

Website

https://www.bauschhealth.com

Bausch Health Companies Inc is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.

Executives

Seana Carson	officer: EVP, General Counsel	400 SOMERSET CORPORATE BLVD, BRIDGEWATER NJ 08807
John S Barresi	officer: SVP, Controller & CAO	727 FIFTH AVENUE, NEW YORK NY 10022
Richard Mulligan	director	C/O ICAHN CAPITAL LP, 767 FIFTH AVENUE, SUITE 4700, NEW YORK NY 10153
Tom George Vadaketh	officer: EVP, Chief Financial Officer	1727 JOCKEYS WAY, YARDLEY PA 19067
Robert Spurr	director, officer: U.S. President-Pharma Business	C/O BAUSCH HEALTH COMPANIES INC., 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Joseph F Gordon	officer: Pres&Co-Head Bausch&Lomb/Int'l	C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Frederick Munsch	officer: SVP, Controller and CAO	C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Christina Ackermann	officer: EVP AND GENERAL COUNSEL	C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Sam Eldessouky	officer: EVP & Chief Financial Officer	C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Steven D Miller	director	16690 COLLINS AVENUE, PH, SUNNY ISLE BEACH FL 33160
Von Eschenbach Andrew C.	director	C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
De Schutter Richard U	director	C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Brett Icahn	director	C/O ICAHN ENTERPRISES L.P., 16690 COLLINS AVE., PH, SUNNY ISLES FL 33160
William D. Humphries	officer: EVP, COMPANY GROUP CHAIRMAN	C/O STRATA SKIN SCIENCES, INC., 5 WALNUT GROVE DRIVE SUITE 140, HORSHAM PA 19044
Valueact Capital Master Fund, L.p.	director, other: See remarks	ONE LETTERMAN DRIVE, BUILDING D, 4TH FLOOR, SAN FRANCISCO CA 94129